Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion Announces Submissions of Two NDAs and Official Completion of Two MAA Validations for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
ANN ARBOR, Mich., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that the company has successfully completed important and key global marketing applications including the submission of two New Drug Applications (NDAs) for bempedoic acid and the bempedoic acid / ezetimibe
Toggle Summary Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review
– Bempedoic Acid is an Oral, Once-daily ATP Citrate Lyase (ACL) Inhibitor that Reduces Cholesterol and Fatty Acid Synthesis in the Liver – – February 21, 2020 PDUFA Target Date Goal for Bempedoic Acid and February 26, 2020 PDUFA Target Date Goal for the Bempedoic Acid / Ezetimibe Combination Tablet
Toggle Summary Esperion to Participate in Upcoming Investor Conferences
ANN ARBOR, Mich., May 28, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will participate in analyst-led fireside chats with investors at the following conferences: Jefferies Healthcare Conference in New York on Wednesday, June 5, 2019 at 8:30 a.m. E.T.
Toggle Summary Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
1002-035 Study Meets Primary Endpoint of Incremental LDL-C Lowering Added to Atorvastatin 80 mg Bempedoic Acid Had No Effect on the PK of Atorvastatin and Was Observed to be Safe and Well-Tolerated  Conference Call and Webcast on October 13, 2016 at 8:00 a.m. Eastern Time ANN ARBOR, Mich., Oct.
Toggle Summary Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical Innovation Summit on Wednesday, October 23 rd . The Summit was comprised of a panel of physicians and